Literature DB >> 33027348

Factors associated with Severe Acute Respiratory Syndrome in a Brazilian central region.

Kamilla Lelis Rodrigues de Araujo1, Érika Carvalho de Aquino2, Lara Lívia Santos da Silva2, Yves Mauro Fernandes Ternes2.   

Abstract

Severe Acute Respiratory Infection (SARI) is a notifiable syndrome that must be investigated. This study aimed to analyze the epidemiological profile and factors associated with SARI-related hospitalization and deaths reported in Goiás. Retrospective cohort study, with data from the investigation files of the Notifiable Diseases Information System's Influenza Web. Multivariate analysis methods were employed to verify the association between exposure variables with the outcomes of ICU admission and death. A total of 4,832 SARI cases were reported in Goiás from 2013 to 2018. The primary etiological diagnosis was Influenza A (22.3%) with the predominant subtype A (H1N1pdm09), followed by the Respiratory Syncytial Virus. A total of 34.6% of the patients required ICU admission, and 19% died. A longer time to start treatment with antivirals was associated with a higher likelihood to have an ICU admission, while a previous non-vaccination against Influenza, longer time to start treatment, and older age were associated with a higher likelihood to suffer death. The study showed a high frequency of respiratory diseases caused by the Influenza virus in Goiás and that the severity of the syndrome, characterized by ICU admission and deaths, is associated with the start of antiviral treatment vaccine status, and patient's age.

Entities:  

Mesh:

Year:  2020        PMID: 33027348     DOI: 10.1590/1413-812320202510.2.26802020

Source DB:  PubMed          Journal:  Cien Saude Colet        ISSN: 1413-8123


  1 in total

1.  Severe acute respiratory syndrome and COVID-19 under the hierarchy of the urban network of municipalities in the state of Acre, western Brazilian Amazon region, 2020-2021: a cross-sectional study.

Authors:  Mário Ribeiro Alves; Erlei Cassiano Keppeler
Journal:  Sao Paulo Med J       Date:  2022 Sep-Oct       Impact factor: 1.838

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.